The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial - OCEAN
Summary
Atrial fibrillation is an abnormal heart rhythm in which can increase the risk of developing clots in the heart which can then break off and travel to the brain and cause a stroke.
Catheter ablation is a procedure which is used to restore the regular rhythm of the heart; however even when this treatment is successful, patients still may have an increased risk of having a stroke compared to people who have never had atrial fibrillation.
Two types of medication are presently prescribed to patients following their catheter ablation (even if it appears to have been successful in eliminating atrial fibrillation): an antiplatelet (such as aspirin), or an anticoagulant (also known as a blood thinner). This study is being done in order to find out which type of medication works best for preventing strokes in people who have had a successful catheter ablation.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 18 to 85
Accepts healthy participants: Yes
Inclusion criteria:
->18 years old
-At least 1 year following successful catheter ablation for AF (Holter monitor reports required)
-Acceptable stroke risk score (determined by physician)
Exclusion criteria:
-Unable to use blood thinners
-Kidney disease
-Metal heart valve
-Unable to have MRI
-Stroke within 1 year
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Jennifer McKeage R.N. jmckeage@ucalgary.ca 403-210-6047
Principal investigator:
F. Russell Quinn
Clinical trial:
Yes
REB-ID:
REB16-1137